XFOR Stock Overview
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
X4 Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.29 |
| 52 Week High | US$2.58 |
| 52 Week Low | US$0.57 |
| Beta | 0.46 |
| 1 Month Change | -11.64% |
| 3 Month Change | 74.75% |
| 1 Year Change | -14.00% |
| 3 Year Change | -85.09% |
| 5 Year Change | -93.80% |
| Change since IPO | -91.51% |
Recent News & Updates
Recent updates
Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?
Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?
Apr 19Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?
Oct 07X4 Pharmaceuticals: Upcoming Catalysts
Sep 19X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%
Jul 20X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended
Jul 01X4 Pharma: Late Stage Nanocap Targeting Rare Diseases
Aug 03Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?
Jun 22X4 Pharmaceuticals EPS misses by $0.44
May 06How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?
Mar 16X4 Pharmaceuticals EPS misses by $0.12
Nov 05Shareholder Returns
| XFOR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.9% | 1.0% | 1.2% |
| 1Y | -14.0% | 0.7% | 24.9% |
Return vs Industry: XFOR underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: XFOR underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| XFOR volatility | |
|---|---|
| XFOR Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: XFOR's share price has been volatile over the past 3 months.
Volatility Over Time: XFOR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 93 | Paula Ragan | www.x4pharma.com |
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases.
X4 Pharmaceuticals, Inc. Fundamentals Summary
| XFOR fundamental statistics | |
|---|---|
| Market cap | US$206.56m |
| Earnings (TTM) | -US$101.17m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.1x
P/E RatioIs XFOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XFOR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$101.17m |
| Earnings | -US$101.17m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.60 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 106.8% |
How did XFOR perform over the long term?
See historical performance and comparison